Treatment for peritoneal dialysis-associated peritonitis

Area of Science:

• Nephrology
• Infectious Diseases
• Clinical Trials

Background:

• Peritonitis is a frequent and serious complication of peritoneal dialysis (PD).
• Effective treatment is crucial to minimize patient morbidity and prevent recurrent infections.

Purpose of the Study:

• To systematically evaluate the efficacy and safety of various treatment strategies for peritonitis in PD patients.
• To compare different antibiotic administration routes, doses, schedules, and alternative interventions.

Main Methods:

• Comprehensive search of multiple databases (Cochrane Renal Group, CENTRAL, MEDLINE, EMBASE) up to February 2005.
• Inclusion of randomized controlled trials (RCTs) and quasi-RCTs assessing antibiotic treatments, fibrinolytic agents, peritoneal lavage, and catheter removal.
• Data extraction on study quality and outcomes, analyzed using random effects models with relative risks and mean differences.

Main Results:

• No single antibiotic agent or combination demonstrated superiority; however, glycopeptide regimens showed higher complete cure rates than cephalosporins.
• Intraperitoneal (IP) antibiotic administration was more effective than intravenous (IV) in reducing treatment failure.
• Simultaneous catheter removal/replacement outperformed urokinase for relapsing/persistent peritonitis; continuous and intermittent IP dosing showed similar efficacy.
• Methodological quality of studies was often suboptimal, with inconsistent outcome definitions.

Conclusions:

• Intraperitoneal antibiotic administration is favored over IV for PD peritonitis based on available evidence.
• Both continuous and intermittent IP antibiotic dosing regimens are equally effective.
• Routine peritoneal lavage and urokinase lack demonstrated benefit; no interventions showed significant harm.